Zai Lab to Present New Oncology Research at 2022 Society for Immunotherapy of Cancer Annual Meeting
08 nov. 2022 08h30 HE
|
Zai Lab Limited
SHANGHAI and CAMBRIDGE, Mass., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, will...
Zai Lab Announces the Appointment of Dr. Peter Huang as Chief Scientific Officer
08 nov. 2022 07h30 HE
|
Zai Lab Limited
SHANGHAI and CAMBRIDGE, Mass., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today...
Zai Lab Announces Participation in November Investor Conferences
31 oct. 2022 07h52 HE
|
Zai Lab Limited
SHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass., Oct. 31, 2022 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global...
Zai Lab to Announce Third Quarter 2022 Financial Results on November 9, 2022
18 oct. 2022 07h30 HE
|
Zai Lab Limited
SHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass., Oct. 18, 2022 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global...
Zai Lab Launches its first Trust Report
14 oct. 2022 07h55 HE
|
Zai Lab Limited
Zai Lab is committed to earning your trust through our environmental, social, and governance (ESG) strategy, which we are calling Trust for LifeZai’s Trust for Life strategy includes three commitments...
Seagen and Zai Lab Announce Regional Strategic Collaboration and License Agreement for TIVDAK® (tisotumab vedotin-tftv)
27 sept. 2022 08h00 HE
|
Zai Lab Limited
-- Zai Lab Obtains Exclusive Rights to Develop and Commercialize TIVDAK, an FDA-approved First-in-Class Antibody-Drug Conjugate (ADC), in Mainland China, Hong Kong, Macau, and Taiwan -- -- Zai Lab...
Zai Lab to Present Analysis of the Impact of Timing for ZEJULA® (niraparib) Maintenance Treatment in Newly Diagnosed Advanced Ovarian Cancer at the 2022 International Gynecologic Cancer Society Meeting
20 sept. 2022 08h03 HE
|
Zai Lab Limited
SHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass., Sept. 20, 2022 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global...
Zai Lab Announces Participation in September Investor Conferences
23 août 2022 07h30 HE
|
Zai Lab Limited
SHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass., Aug. 23, 2022 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global...
Zai Lab Announces Second Quarter 2022 Financial Results and Corporate Updates
09 août 2022 16h05 HE
|
Zai Lab Limited
Key pipeline milestones achieved including the BLA acceptance of efgartigimod by China’s NMPA and positive topline results for the KarXT Phase 3 EMERGENT-2 trial Continued revenue growth led by...
Zai Lab Partner Karuna Therapeutics Announces Positive Results from Phase 3 EMERGENT-2 Trial of KarXT in Schizophrenia
08 août 2022 07h02 HE
|
Zai Lab Limited
Trial met primary endpoint, with KarXT demonstrating a statistically significant 9.6-point reduction in PANSS Total Score compared to placebo at Week 5 (p<0.0001) Trial also met key secondary...